Medpace Holdings, Inc.
MEDPNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MEDP. That does not mean none is planned.
Get an email about MEDP's next catalysts
Track Medpace Holdings (MEDP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Websiteomega-3-carboxylic acids
Hypertriglyceridemia
[18F] Flutemetamol
Healthy
lerodalcibep
Heterozygous Familial Hypercholesterolemia
Pritelivir
HSV Infection
dalcetrapib
Acute Coronary Syndrome
cefepime/AAI101 combination
Urinary Tract Infections
Cefepime-zidebactam (FEP-ZID)
Complicated Urinary Tract Infection
rugonersen
Angelman Syndrome
ZTI-01
Urinary Tract Infection Symptomatic
VI-0521
Obesity
Cefepime -/AAI101
Urinary Tract Infections
MultiStem
Ischemic Stroke
Etripamil
Paroxysmal Supraventricular Tachycardia (PSVT)
CXA-10
Primary Focal Segmental Glomerulosclerosis
LIB003
LDL Cholesterol
Azeliragon
Glioblastoma
Diazoxide Choline Controlled-Release Tablet
Hypertriglyceridemia
Diazoxide choline
Hypertriglyceridemia
MEN1703
Acute Myeloid Leukemia
Pyridoxamine Dihydrochloride
Diabetic Nephropathy
Statin Therapy
Hypercholesterolemia
Avacopan
C3 Glomerulopathy (C3G)
AVM0703
Lymphoid Malignancies
MBN-101
Bacterial Infection
patiromer
Hyperkalemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
omega-3-carboxylic acids | Phase 3 | Hypertriglyceridemia | - | - |
[18F] Flutemetamol | Phase 3 | Healthy | - | - |
lerodalcibep | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
Pritelivir | Phase 3 | HSV Infection | - | - |
dalcetrapib | Phase 3 | Acute Coronary Syndrome | - | - |
cefepime/AAI101 combination | Phase 3 | Urinary Tract Infections | - | - |
Cefepime-zidebactam (FEP-ZID) | Phase 3 | Complicated Urinary Tract Infection | - | - |
rugonersen | Phase 3 | Angelman Syndrome | - | - |
ZTI-01 | Phase 3 | Urinary Tract Infection Symptomatic | - | - |
VI-0521 | Phase 3 | Obesity | - | - |
Cefepime -/AAI101 | Phase 2 | Urinary Tract Infections | - | - |
MultiStem | Phase 2 | Ischemic Stroke | - | - |
Etripamil | Phase 2 | Paroxysmal Supraventricular Tachycardia (PSVT) | - | - |
CXA-10 | Phase 2 | Primary Focal Segmental Glomerulosclerosis | - | - |
LIB003 | Phase 2 | LDL Cholesterol | - | - |
Azeliragon | Phase 2 | Glioblastoma | - | - |
Diazoxide Choline Controlled-Release Tablet | Phase 2 | Hypertriglyceridemia | - | - |
Diazoxide choline | Phase 2 | Hypertriglyceridemia | - | - |
MEN1703 | Phase 2 | Acute Myeloid Leukemia | - | - |
Pyridoxamine Dihydrochloride | Phase 2 | Diabetic Nephropathy | - | - |
Statin Therapy | Phase 2 | Hypercholesterolemia | - | - |
Avacopan | Phase 2 | C3 Glomerulopathy (C3G) | - | - |
AVM0703 | Phase 2 | Lymphoid Malignancies | - | - |
MBN-101 | Phase 2 | Bacterial Infection | - | - |
patiromer | Phase 2 | Hyperkalemia | - | - |
Frequently asked questions
What is in Medpace Holdings, Inc.'s drug pipeline?β
CatalystAlert tracks 25 drug candidates in Medpace Holdings, Inc.'s (MEDP) pipeline across Phase 3, Phase 2. Its lead program is [18F] Flutemetamol (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Medpace Holdings, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Medpace Holdings, Inc. (MEDP) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track MEDP biotech catalysts?β
Add MEDP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medpace Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
